Modified intrapleural cisplatin treatment for lung cancer with positive pleural lavage cytology or malignant effusion.
OBJECTIVE
We evaluate the efficacy and safety of the modified intrapleural cisplatin treatment for lung cancer patients with positive pleural lavage cytology or malignant effusion.


METHODS
The treatment was performed for seven patients with malignant effusion and 18 patents with positive pleural lavage cytology. After pulmonary resection, the pleural cavity was filled with cisplatin with a normal saline solution for 30 min. Complications and survival of the patients were evaluated.


RESULTS
The chest tube duration were significantly prolonged in the treatment (CDDP) group (5.7 +/- 3.6 vs. 2.8 +/- 2.6 days). We had one operative death that developed a bronchial fistula; however, the other complications were not severe. The mortality rate was 4% and the morbidity rate was 60%. We experienced two carcinomatous pleuritis in the CDDP group. The median survival time of the CDDP group was 47.0 +/- 11.1 months and the 3- and 5-year survival rate was 52.6% and 11.3%, respectively.


CONCLUSIONS
We were able to perform this treatment for these advanced lung cancer patients, which had the preventive effect of carcinomatous pleuritis. This therapy shows the possibility of a treatment that might lead to an improvement in the prognosis of these patients, without causing severe complications.
Muraoka
Masashi
M
Division of Surgical Oncology, Department of Translational Medical Sciences, Nagasaki Graduate School of Biomedical Sciences, Nagasaki, Japan. ceb17760@hkg.odn.ne.jp
Oka
Tadayuki
T
Akamine
Shinji
S
Tagawa
Tsutomu
T
Morinaga
Masafumi
M
Inoue
Masao
M
Yamayoshi
Takatomo
T
Hashizume
Satoshi
S
Matsumoto
Keitaro
K
Hayashi
Tomayoshi
T
Nagayasu
Takeshi
T
D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001992:Bronchoalveolar Lavage Fluid / Q000166:cytology; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D002945:Cisplatin / Q000008:administration & dosage*; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D007430:Intraoperative Care; D008175:Lung Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D035422:Pleural Cavity; D016066:Pleural Effusion, Malignant / Q000188:drug therapy* / Q000473:pathology; D011013:Pneumonectomy; D015996:Survival Rate
D000970:Antineoplastic Agents; D002945:Cisplatin